J Gynecol Oncol.  2009 Sep;20(3):199-199. 10.3802/jgo.2009.20.3.199.

In reply: Different role of secondary cytoreductive surgery by surgeon's experience and hospital facility

• Lim MC
• Bae J
• Park SY

• KMID: 2173457
• DOI: http://doi.org/10.3802/jgo.2009.20.3.199

Abstract

No abstract available.

Reference

1. Bae J, Lim MC, Choi JH, Song YJ, Lee KS, Kang S, et al. Prognostic factors of secondary cytoreductive surgery for patients with recurrent epithelial ovarian cancer. J Gynecol Oncol. 2009. 20:101–106.

2. Chi DS, McCaughty K, Diaz JP, Huh J, Schwabenbauer S, Hummer AJ, et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer. 2006. 106:1933–1939.

3. Defining Therapy for Recurrent Platinum-sensitive Ovarian Cancer [Internet]. National Cancer Institute. c2009. cited 2009 Sep 12. Bethesda: National Cancer Institute;Available from: http://www.cancer.gov/clinicaltrials/ft-GOG-0213.

4. Lim MC, Lee HS, Jung DC, Choi JY, Seo SS, Park SY. Pathological diagnosis and cytoreduction of cardiophrenic lymph node and pleural metastasis in ovarian cancer patients using video-assisted thoracic surgery. Ann Surg Oncol. 2009. 16:1990–1996.